Literature DB >> 21989073

Targeted therapies: A new success for an antiangiogenic?

Rebecca Kirk.   

Abstract

Year:  2011        PMID： 21989073     DOI： 10.1038/nrclinonc.2011.150

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Authors:  Roberto Pili; Michael Häggman; Walter M Stadler; Jeffrey R Gingrich; Vasileios J Assikis; Anders Björk; Orjan Nordle; Goran Forsberg; Michael A Carducci; Andrew J Armstrong
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.